Does dexrazoxane reduce cardiotoxicity and affect the risk of second malignant neoplasms in children receiving anthracycline chemotherapy?
Dexrazoxane reduces cardiotoxicity in children receiving anthracyclines but may carry a borderline increased risk of second malignant neoplasms, requiring individualized risk-benefit assessment.
Dexrazoxane is associated with a statistically significant risk reduction for most cardiotoxic outcomes. Dexrazoxane is associated with a statistically borderline increase in SMNs, possibly because of an interaction with concurrent cancer therapies. The decision to use dexrazoxane in children should balance the risks of cardiotoxicity and SMNs specific to each treatment protocol.
Shaikh et al. (Mon,) studied this question.